Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis

Cornec, Divi; Pensec, V. Devauchelle; Joulin, S. Jousse; Saraux, Alain

doi:10.1002/art.24597

Cited by 33 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, both procedures risk significant complications in patients with ankylosing spondylitis 2. There are two case reports describing the successful treatment of the syndrome using the tumour necrosis factor-α antagonist, infliximab,5 6 with resolution of faecal incontinence in one5 and partial relief of radicular pain and faecal incontinence in the other 6. These two patients reported only subjective benefits without improvement in objective neurological signs (unlike in this case).…”

Section: Discussionmentioning

confidence: 65%

Horse's tail in bamboo spine: the ‘cauda equina syndrome in ankylosing spondylitis’

Nair

Romanowski

et al. 2014

Pract Neurol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 65%

Horse's tail in bamboo spine: the ‘cauda equina syndrome in ankylosing spondylitis’

Nair

Romanowski

et al. 2014

Pract Neurol

View full text Add to dashboard Cite

“…The role of immunosuppressants in these cases is unclear. One patient with cauda equina syndrome secondary to AS was successfully treated with infliximab [68], while in another case of acute transverse myelitis in a patient with psoriatic arthritis, a high dose of methylprednisolone resulted in symptom amelioration [69].…”

Section: Inflammatory Arthritismentioning

confidence: 99%

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

et al. 2016

View full text Add to dashboard Cite

Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example antitumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients.

show abstract

“…Lumbo--peritoneal decompression and infliximab have both been reported to be effective treatments 40, 41 .…”

Section: Surgical Considerationsmentioning

confidence: 99%

Physical Therapy and Surgery

Valle-Oñate

Ward

Kerr

et al. 2012

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Physical therapy and orthopedic surgery are important components in the treatment of ankylosing spondylitis (AS). Supervised physical therapy is more effective that individual or unsupervised exercise in improving symptoms, but controlled trials suggest than combined inpatient and outpatient therapy provides the greatest improvement. Recommendations for exercise are universal, but the best types and sequence of therapies are not known. Total hip replacement is the surgery most commonly performed for AS, with good long-term implant survival. Heterotopic ossification may occur no more frequently after hip replacement in patients with AS than in patients with other diseases. Corrective spinal surgery is rarely performed and requires specialized centers and experienced surgeons.

show abstract

Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis

Cited by 33 publications

References 14 publications

Horse's tail in bamboo spine: the ‘cauda equina syndrome in ankylosing spondylitis’

Horse's tail in bamboo spine: the ‘cauda equina syndrome in ankylosing spondylitis’

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity

Physical Therapy and Surgery

Contact Info

Product

Resources

About